News

WP4 aims to develop a starter set of assays addressing different preclinical safety issues of nanobiomaterials requested by regulatory agencies. For this purpose assays which were previously developed in the partner laboratories are performed and compared to each other to identify the optimal assay sets.

Representatives from each member of WP4 met in Düsseldorf airport for a one-day-meeting to discuss the current development of the starter assay set for nanobiomaterials. Current assay results were presented and discussed between the members with regards to applicability, reproducibility and performance. The members agreed on next steps to proceed and will develop SOPs for the starter set assays which will be checked for quality assurance under guidance of WP5 afterwards.